Search Results

Why: A Memoir of Love and Lymphoma by John Melithoniotes
NFB Publishing, 2023, 278 Pages, Paperback or Kindle
ISBN: 9781953610485

There is no test of a couple’s bonds like the revelation that one of them has a life-threatening disease. One of them, a husband, wife, or partner, will become a patient who may need care from the other almost constantly. This is the story of John and Marilyn, whose love of nearly forty years encounters a diagnosis of Marilyn’s Non-Hodgkin’s lymphoma. John’s memoir describes the complexities of how they navigated their way through a large urban cancer hospital, their daily attempts to manage the side effects of chemotherapy, and their emotional struggle to cope with a worsening crisis. He revisits key scenes from their lives in the hope of understanding their actions and the surprises in store for both of them.

For more information click here

Suggested Reading-Why: A Memoir of Love and Lymphoma

Audience

Adults

Subject

Caregiving Decision Making Grief Inspiration Living with Cancer/Survivorship Side Effects Treatments

Spotlight On Mantle Cell Lymphoma

A Brave Kid’s Guide to Lymphoma

A Brave Kid’s Guide to Lymphoma by Nina Gonzalez, MD
Hello Brave Co, 2024, 49 Pages, Paperback
ISBN: 979-8990710511

Charlie is a curious kid facing a big challenge: lymphoma. With so many questions swirling in his mind, Charlie finds a friend in Cobi, the super smart Brave Buddy who helps kids understand their medical diagnoses. Together, they set off on a journey of understanding, and Charlie realizes just how Brave he is.

A Brave Kid's Guide to Lymphoma is designed to help children understand their lymphoma diagnosis. Created by Dr. Nina Gonzalez and the Hello Brave team, this book breaks down complex medical information into simple, clear language and illustrations. Through an engaging conversation between Cobi and Charlie, this book helps to dispel common misconceptions and provides comfort through a shared understanding of this challenging diagnosis. At the end of the book, you'll find a glossary of easy-to-understand terms, guides for adults on how to talk about tough diagnoses like lymphoma with kids, questions to ask your care team, and a Brave Kid Certificate to honor your child's bravery and strength. This book is a supportive tool for both patients and families dealing with lymphoma.

For more information click here

Suggested Reading - A Brave Kid’s Guide to Lymphoma

Audience

Teens & Children

Targeting mutant IDH2 in angioimmunoblastic T-cell lymphoma

Angioimmunoblastic T-cell lymphoma is a rare, aggressive form of T-cell lymphoma associated with poor clinical outcomes in response to current therapeutic approaches. Recurrent oncogenic mutations in isocitrate dehydrogenase 2 (IDH2) have been identified in patients with angioimmunoblastic T-cell lymphoma and this represents a targetable lesion in other malignancies. However, comprehensive investigations of mutant IDH2 inhibition in angioimmunoblastic T-cell lymphoma are lacking, and this may represent a new therapeutic avenue for a patient population in need of newer treatments

Bispecific antibody-based frontline therapy for follicular lymphoma

We are conducting a clinical trial testing a novel form of immunotherapy, called a bispecific antibody, as part of initial treatment for patients with follicular lymphoma. The goal of the trial is two-fold: 1) to establish a highly effective, chemotherapy-free treatment option for patients with follicular lymphoma, and 2) to establish predictors of response and toxicity that can guide treatment decisions for future patients with follicular lymphoma.

Role of ID2 in mature T-cell lymphoma

Overexpression of ID2 is a recurrent event in mature T-cell lymphoma (TCL), and its significance is yet to be established. We will use a multidisciplinary approach combining epigenetic, transcriptomic, and proteomic analysis in human and murine models to identify the mechanisms leading to ID2 overexpression and their effect on T-cell transformation. Our goal is to define the role of ID2 in lymphomagenesis and determine its potential as a novel therapeutic target in TCL.

Towards Risk-Adapted Therapeutic Strategies in CNS Lymphoma

This project will significantly advance the treatment and prevention of CNS lymphomas in two key areas. One, we will further develop and validate candidate genomic biomarkers that identify high risk disease and that are useful in risk stratification in future clinical investigations in primary CNS lymphoma.

Overcoming ibrutinib resistance in mantle cell lymphoma

Mantle cell lymphoma (MCL) is an aggressive blood cancer which affects about 3,000 individuals in the United States annually. Despite advances of novel therapies in blood cancers, MCL remains incurable, and patients ultimately succumb to disease. We seek to evaluate longitudinal samples from patients with MCL treated with novel therapies to understand the mechanisms of drug resistance. We identify novel targets, with a particular focus on protein turnover pathways, to overcome drug resistance and improve survival of patients with MCL.

Lisocabtagene maraleucel

Lisocabtagene maraleucel is indicated for the treatment of

Central Nervous System (CNS) Lymphoma

General Information

Central nervous system lymphoma is a rare non-Hodgkin lymphoma in which malignant (cancer) cells from lymph tissue form in the brain and/or spinal cord (primary CNS) or spread from other parts of the body to the brain and/or spinal cord (secondary CNS). Because the eye is so close to the brain, primary CNS lymphoma can also start in the eye (called ocular lymphoma). The cancer can also involve the spinal fluid that bathes the spinal cord and brain. This is called leptomeningeal lymphoma. Both primary and secondary CNS lymphomas are rare diseases.

Next-Generation Targeted Therapy in Mantle Cell Lymphoma and Transformed Follicular Lymphoma

Brentuximab vedotin

Brentuximab vedotin is FDA approved for the treatment of:

Epcoritamab-bysp

Epcoritamab-bysp is indicated for the treatment of

Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma
- Adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from indolent lymphoma, and high-grade B-cell lymphoma after two or more lines of systemic therapy
Follicular Lymphoma
- Adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy

Axicabtagene ciloleucel

Axicabtagene ciloleucel is a CD19-directed genetically modified autologous T cell immunotherapy indicated for the treatment of:

Highlights from ASH 2021

The American Society of Hematology (ASH) annual meeting is the premier scientific forum on blood cancers. More than 5,000 potentially game-changing research abstracts were presented at this year’s meeting. Every year, I come away with a strengthened sense of hope about new treatments on the horizon and renewed pride in The Leukemia & Lymphoma Society’s (LLS) role in supporting so many of them.

JAK/STAT inhibition as a therapeutic strategy in T-cell lymphoma

Given the high rate of JAK/STAT pathway dysregulation in T-cell lymphomas, we aim to develop new personalized therapies with JAK inhibitors for T-cell lymphoma. Our recent study with ruxolitinib (a JAK inhibitor) showed that activation of a parallel oncogenic pathway, PI3-kinase, predicts for poor response to ruxolitinib in T-cell lymphoma. Building upon this observation, we are assessing whether dual inhibition of JAK and PI3-Kinase will lead to higher efficacy in T-cell lymphoma.

Diagnosed with a Blood Cancer? Important Questions You Might Not Think to Ask

What is my actual diagnosis? Find out your exact diagnosis. Ask your doctor to write down the exact name of your sub-type and take the paper with you. For example, knowing you have “a B-cell lymphoma” isn’t good enough. Follicular and diffuse large B-cell are both B-cell lymphomas but with very different prognoses and treatment plans. Leukemia also has different sub-types. Knowing your specific sub-type helps you understand what disease you are dealing with, how aggressive it is, and what to expect from treatment.

Rituximab and hyaluronidase human

Rituximab and hyaluronidase human is a combination of rituximab, a CD20-directed cytolytic antibody, and hyaluronidase human, an endoglycosidase, indicated for the treatment of adult patients with:

A researcher analyzes a specimen in a test tube.

Blood Cancer Research Poised for Another ‘Banner Year’ in 2024

More than 25,000 medical professionals from across the world came together in December to discuss the latest blood cancer developments during the annual meeting of the American Society of Hematology (ASH). This annual event gives us the opportunity to think about what advances are on the horizon as LLS works to strengthen cures, care and quality of life for people with blood cancer and their families.

Tisagenlecleucel

Tisagenlecleucel is a CD19-directed genetically modified autologous T cell immunotherapy indicated for the treatment of

Restoring lymphoma immunosurveillance by combined EZH2 inhibition and immunotherapy

The project builds on evidence that mutations leading to persistent EZH2 activation drive germinal center B-cell lymphomagenesis by disrupting T-cell surveillance, and will test the hypothesis that EZH2 inhibition synergizes with immune checkpoint blockade and/or co-stimulation to eradicate these diseases. These results will provide the rationale for clinical development of precision-medicine immune-epigenetic combination therapies for lymphomas where these mechanisms are specifically altered.